Growing at a compound annual growth rate (CAGR) of 5.2%, the market is expected to reach approximately USD 205.3 ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Slone Partners, a premier executive search and talent advisory firm for life sciences and healthcare organizations, has named ...
In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA Signature program, an innovative approach ...
A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study, published in ...
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
We recently published a list of 11 Best Bear Market Stocks To Invest In Now. In this article, we are going to take a look at ...
William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.
Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...
AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.